BUSINESSFINANCIAL TIMES WORLD
The $400bn megadeal brewing in big pharma
AstraZeneca and Bristol Myers Squibb are in talks that could result in a $400bn merger, creating the world’s fourth-largest drugmaker by market value.
Mentioned
Related Signal
Adjacent reporting
- AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
- AstraZeneca Said to Have Explored Bristol Myers Merger
- AstraZeneca said to have explored Bristol Myers merger